# Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

> **NCT05089734** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 603 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Sacituzumab Govitecan-hziy (SG)
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05089734
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-17
- **Primary completion:** 2023-11-29
- **Final completion:** 2027-01
- **Target enrollment:** 603 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089734, "Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05089734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*